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Abstract
Background: Intact LINE-1 elements are the only retrotransposons encoded by the human genome known to be capable of
autonomous replication. Numerous cases of genetic disease have been traced to gene disruptions caused by LINE-1
retrotransposition events in germ-line cells. In addition, genomic instability resulting from LINE-1 retrotransposition in
somatic cells has been proposed as a contributing factor to oncogenesis and to cancer progression. LINE-1 element activity
may also play a role in normal physiology.
Methods and Principal Findings: Using an in vitro LINE-1 retrotransposition reporter assay, we evaluated the abilities of
several antiretroviral compounds to inhibit LINE-1 retrotransposition. The nucleoside analogue reverse transcriptase
inhibitors (nRTIs): stavudine, zidovudine, tenofovir disoproxil fumarate, and lamivudine all inhibited LINE-1 retrotranspo-
sition with varying degrees of potencies, while the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine showed
no effect.
Conclusions/Significance: Our data demonstrates the ability for nRTIs to suppress LINE-1 retrotransposition. This is
immediately applicable to studies aimed at examining potential roles for LINE-1 retrotransposition in physiological
processes. In addition, our data raises novel safety considerations for nRTIs based on their potential to disrupt physiological
processes involving LINE-1 retrotransposition.
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Introduction
One of the most striking discoveries resulting from the human
genome sequencing project was the observation that our genome is
42% comprised of retrotransposable element (RE) sequence [1].
Long interspersed nuclear element 1 (LINE-1) elements represent
the most prolific class of RE, and alone make up 17% of genomic
sequences. An estimated 100 retrotransposition competent LINE-
1 elements remain in the human genome, of which a small number
(6 in the December 2001 freeze of the human genome working
draft) are classified as highly active [2,3]. Intact LINE-1 elements
contain two ORFs. ORF1 encodes a 40 kDa protein with RNA
chaperone activity, while ORF2 encodes a 150 kDa protein which
possesses the endonuclease and reverse transcriptase (RT) activities
required for retrotransposition [4–13]. Retrotransposition occurs
by a mechanism termed target-primed reverse transcription
(TPRT) where reverse transcription and integration are coupled
as a single concerted step at the site of insertion [14–16].
Initial evidence for the presence of retrotransposition competent
LINE-1 elements in the human genome was provided by the
discovery of LINE-1 insertions into exon 14 of the factor VIII gene
in two unrelated haemophilia patients [17]. Many additional cases
of genetic disease have since been traced to LINE-1 retrotrans-
position mediated gene disruptions in the germ-line. These
include, amongst others, the insertion of a LINE-1 sequence into
intron 5 of the X-linked gene CYBB resulting in aberrant splicing,
and manifesting as chronic granulomatous disease, and the
insertion of LINE-1 sequence into the 39 end of exon 44 of the
dystrophin gene resulting in a case of Duchenne muscular
dystrophy [18–21]. LINE-1 retrotransposition in somatic cells
has also been reported, and this likely contributes to some cases of
carcinogenesis [22]. This is highlighted by the identification of a de
novo LINE-1 insertion into the APC tumor suppressor gene in
colon cancer [23]. Genomic instability induced by LINE-1
retrotransposition may also play a role in the progression of
malignancies. A recent study found that LINE-1 promoter
hypomethylation, and associated transcription, was significantly
more frequent in blast-phase chronic myeloid leukemia (CML)
than in chronic-phase CML, and that LINE-1 hypomethylation
was prognostic of poorer progression-free survival [24].
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retrotransposition in pathological conditions, the activity of LINE-
1 elements may also play a role in normal physiology. Specifically, it
has been suggested that LINE-1 retrotransposition may mediate the
generation of neuronal somatic mosaicism during development [25].
Thus there is a two-fold requirement to study pharmacalogical
agents with activity against LINE-1 elements. Suppression of LINE-
1 elements may provide benefits in cases where their continued
activity contributes to pathology, and conversely, inadvertent
suppression of LINE-1 elements by agents employed to treat disease
states may disrupt LINE-1-mediated physiological processes.
The nucleoside analogue reverse transcriptase inhibitor (nRTI)
class of antiviral compounds inhibit a broad range of nucleic acid
polymerases including viral RTs, and cellular DNA polymerases.
While the prototypical nucleoside analogue, AZT, was originally
developed for the treatment of cancer, this class of compounds is
now primarily used to treat HIV-1 infection. The safety and utility
of nRTIs is dependent upon these compounds having a much
greater affinity for viral RT than for cellular DNA polymerases.
AZT for example has 100–300 fold greater affinity for HIV-1-RT
than for DNA polymerase [26]. Some nRTIs, including 3TC, are
also effective at suppressing reverse transcription of the hepatitis B
virus [27,28]. Due to their broad ability to suppress RT enzymes,
nRTIs have the potential to suppress LINE-1 retrotransposition.
Supporting this, one previous study reported a suppressive effect of
the nRTI zidovudine (AZT) on LINE-1 retrotransposition [22].
We employed an in vitro LINE-1 retrotransposition assay to
study the effects of nRTIs on LINE-1 retrotransposition. This
system is described in detail elsewhere, and portrayed in Figure 1A
[29]. Briefly, a retrotransposition competent LINE-1 element
(LRE3) was cloned into an expression plasmid, under the control
ofits natural promoter. An eGFP retrotransposition reporter cassette
was then cloned into the 39 UTR of the LINE-1 element. The
cassette consists of an eGFP coding sequence under the control of a
CMV promoter inserted in the opposite orientation as the LINE-1
element. The sequence is disrupted by an intron inserted in the same
transcriptional orientation as the LINE-1 sequence. Thus transcrip-
tion from the eGFP CMV promoter yields an unspliced product due
to the inversion of the intron in the resultant RNA. Transcription
from the LINE-1 promoter yields a spliced transcript, but with an
eGFP gene which cannot be translated due to its 39 to 59 orientation
within the mRNA. Translation of eGFP can only be achieved when
this mRNA is integrated into the genome by reverse transcription,
allowing sense transcription of spliced eGFP from the CMV
promoter. This system is a variation of a neomycin resistance based
retrotranspositionassaywhichwasdevelopedbyHeidmannetal,and
Figure 1. Effect of antiretroviral drugs on LINE-1 retrotrans-
position frequency. A. The LINE-1 retrotransposition reporter
plasmid 99gfpLRE3 encodes the full-length, retrotransposition compe-
tent LRE3 LINE-1 element under the control of its natural promoter. An
eGFP retrotransposition reporter cassette was inserted into the LRE3 39
UTR. The cassette encodes eGFP under the control of a CMV promoter,
in inverse orientation relative to the LRE3 sequence. The eGFP coding
sequence is interrupted by an intron inserted in the same transcrip-
tional orientation as LRE3. Transcription from the CMV promoter does
can not yield a spliced eGFP sequence. Transcription from the LINE-1
promoter does not lead to eGFP expression, as the eGFP coding
sequence is inverted in the resulting mRNA. However, retrotransposi-
tion of this RNA, and integration into the genome, allows a sense eGFP
mRNA to be transcribed from the CMV promoter. Thus in cells
transfected with 99gfpLRE3, eGFP expression acts as a reporter for the
completion of a successful retrotransposition event. The 99gfpJM111
plasmid is analogous to 99gfpLRE3, but incorporates point mutations in
ORF1 which render its LINE-1 element retrotransposition incompetent.
99gfpJM111 was therefore employed as a negative control in all assays.
Both the 99gfpLRE3 and 99gfpJM111 plasmids also encode puromycin
resistance markers allowing for selection of transfected cells. B–D. HeLa
cells were incubated in triplicate with five-fold serial dilutions of
antiretroviral drugs, and transfected with the LINE-1 retrotransposition
reporter plasmid 99gfpLRE3. Transfectants were selected with puromy-
cin. Five days post-transfection, cells were stained with the viability dye
r
7-AAD, and analyzed by FACS. Retrotransposition frequency was
determined by excluding 7-AAD-positive events, and then gating on
the eGFP-positive population. Shown is representative data from one of
three independent experiments. B. In the absence of drugs, a distinct
eGFP-positive population of viable cells, representing cells that have
undergone LINE-1-LRE3 retrotransposition events, is clearly distinguish-
able. Shown is one of six replicates of no drug control. C. In the
presence of elevated concentrations of nRTIs, the eGFP-positive
population is greatly diminished in frequency, indicating suppression
of retrotransposition. Shown is one of three replicates of 25 mM
stavudine treatment. D. LINE-1 retrotransposition, as reported by eGFP
expression, is inhibited by nRTIs in a dose dependent manner, while
nevirapine has no effect. Shown are the mean frequencies of eGFP-
positive cells amongst the viable 7-AAD-negative subsets, as deter-
mined in triplicate, with standard errors represented by error bars.
Dashed horizontal lines indicate 50% and 90% inhibition levels.
doi:10.1371/journal.pone.0001547.g001
nRTI Suppression of LINE-1
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[30] [12].
Results
The nRTIs studied suppressed LINE-1 retrotransposition with
the following hierarchy of potency: stavudine (d4T).lamivudine
(3TC).tenofovir disoproxil fumarate (TFD).zidovudine (AZT)
(Figure 1B–D). The IC
50 values for inhibition of LINE-1
retrotransposition were: stavudine–0.22 mM, lamivudine–1.12 mM,
tenofovir disoproxil fumarate–1.82 mM, zidovudine–2.21 mM
(Table 1). Of the nRTIs tested, only stavudine achieved 90%
inhibition of LINE-1 retrotransposition in this experiment, with an
IC90 of 7.61 mM. As expected, the HIV-1 non-nucleoside analogue
reverse transcriptase inhibitor (nnRTI), nevirapine, had no effect on
LINE-1 retrotransposition. Nevirapine acts by binding to a
hydrophobic pocket adjacent to the catalytic site of HIV-1-RT
[31,32]. Given the dissimilarity of LINE-1 RT and HIV-1 RT, the
presence of an analogous binding site in LINE-1-RT was highly
unlikely. The HIV-1 integrase inhibitor 118-D-24 also exhibited no
suppression of LINE-1 retrotransposition at 5 mM (data not shown).
Discussion
Our study examined the susceptibility of the cloned LINE-1
element LRE3 to nRTIs. Since the estimated 100 copies of intact
LINE-1 elements in the human genome represents a substantial
degree of diversity, it is important to determine whether the data
reported in this study are specific to this particular LINE-1
element, or more globally applicable to the suppression of human
LINE-1 retrotransposition. Remarkably, it has been estimated that
84% of the total LINE-1 retrotransposition potential in the human
genome can be attributed to 6 ‘hot’ LINE-1 elements [3]. This was
determined by cloning 82 intact LINE-1 elements from the
genome, and summing their activities using the same in vitro
retrotransposition assay employed in the current study. In
addition, ‘hot’ LINE-1 elements are the progenitors for the
majority of disease-causing insertional events isolated ex vivo [18].
Brouha et al have determined a consensus sequence for these 6
‘hot’ LINE-1 elements, and demonstrated that a high degree of
similarity of a LINE-1 sequence to this consensus is predictive of
high-level in vitro activity [3]. The LINE-1 element utilized in the
current study (LRE3) is one of the most active human LINE-1
elements studied to date. Consistent with this, the amino acid
sequence of LRE3 ORF2 is identical to the ‘hot’ LINE-1 element
consensus sequence. The data presented here therefore represent
an assessment of the susceptibility of the consensus ‘hot’ LINE-1
sequence to nRTIs, and can be reasonably interpreted as a
representation of the general susceptibility of human LINE-1
retrotransposition to these drugs.
It is important to note that the data presented in this study
cannot be interpreted as an assessment of the general susceptibility
of total endogenous reverse transcriptase to these drugs. Indeed,
while our data demonstrate a lack of inhibition of LINE-1
retrotransposition by nevirapine, Mangiacasale et al have demon-
strated an inhibitory effect for nevirapine on total endogenous RT
activity [33]. This would suggest that nevirapine is capable of
inhibiting other RT enzymes, potentially those encoded by human
endogenous retroviruses (HERVs). Homology between the RT
enzymes of HIV-1 and HERV-K does allow for the speculation
that nevirapine could bind to a hydrophobic pocket in the HERV-
K RT enzyme which bears similarity to its HIV-1 counterpart,
albeit with lower affinity (10 mM of nevirapine was required to
modestly inhibit endogenous RT activity in the study by
Mangiacasale et al).
LINE-1 retrotransposition has been implicated in the genera-
tion of somatic mosaicism of neurons, and other cells over the
course of development [25]. If further studies verify roles for
LINE-1 retrotransposition in normal physiological processes, our
findings may imply an important safety consideration in the future
development of nRTIs. Presently, potential nRTIs are evaluated
to select candidates with a much greater potency against target
pathogen polymerase enzymes than against normal cellular
polymerases. Further selection for compounds that are ineffective
against LINE-1 RT may reduce the potential for side-effects
resulting from inadvertent suppression of LINE-1 mediated
physiological processes. One context where suppression of
LINE-1 by nRTIs may result in side-effects is in the treatment
HIV-1 infection by an antiretroviral (ARV) regimen incorporating
an nRTI backbone. Our data support that nRTIs used in the
treatment of HIV-1 have the potential to suppress physiological
LINE-1 retrotransposition. The IC50 values obtained for stavu-
dine, lamivudine, and zidovudine in this study are achieved by
standard dosing used in the treatment of HIV-1. Administration of
40 mg BID of stavudine results in a Cmax of 2.53 +/2 0.65 mM
[34], while the Cmax for 150 mg BID of lamivudine is 6.54 +/2
2.18 mM [35], and the Cmax for 200 mg zidovudine is 4.80 +/2
1.87 mM [36,37]. In contrast, the Cmax for tenofovir disoproxil
fumarate at 0.47 +/2 0.14 [38], falls below the LINE-1
retrotransposition IC50 value (Table 1). In this regard, stavudine,
which was the most potent of the agents tested at inhibiting LINE-
1 activity, is associated with the greatest degree of mitochondrial
DNA reduction in fat tissue, which is a putative mechanism for
lipoatrophy [39]. Also, the French Pediatric Cohort reported on
twelve HIV-1 negative children with unexplained neurologic
abnormalities who were exposed to nRTIs in utero, and post-
partum for the prevention of maternal-fetal HIV-1 transmission
[40]. As nRTIs can efficiently pass through the placenta and
accumulate in fetal tissues, their potential to lead to such rare
neurological defects by disrupting the physiological retrotranspo-
sition required for the development of somatic mosaicism, or for
other processes, warrants further study [41–45].
The potential implication that nRTIs may be of therapeutic use
against LINE-1 related diseases is at present a hypothetical
interpretation of our data. The genetic diseases that have thus far
been clearly attributed to LINE-1 activity result from a past
insertional mutagenesis event disrupting a gene. Suppression of
further LINE-1 activity will not correct the underlying gene
disruption causing the disease. Any therapies stemming from this
work will therefore depend on treating disease via suppression of
ongoing LINE-1 activity. Further study is required to delineate
any causal relationship between LINE-1 promoter hypomethyla-
tion and the progression of chronic myeloid leukemia, or other
types of malignancies, before inhibition of LINE-1 retrotranspo-
sition could be considered as a potential therapeutic. It is also
important to note that the retrotransposition assay employed in the
Table 1.
LINE-1 IC50 (mM) Cmax (mM) Reference
Stavudine (d4T) 0.22 2.53 +/2 0.65 34
Lamivudine (3TC) 1.12 6.54 +/2 2.18 35
Tenofovir (TFD) 1.82 0.47 +/2 0.14 38
Zidovudine (AZT) 2.21 4.80 +/2 1.87 36,37
doi:10.1371/journal.pone.0001547.t001
nRTI Suppression of LINE-1
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deliver the entire eGFP coding sequence. The suppression of
LINE-1 by nRTIs is expected to occur at the level of reverse
transcription. Given the unique TPRT mechanism of LINE-1
retrotransposition, where integration and reverse transcription
occur in concert, we cannot rule out the possibility that in the
presence of nRTIs the frequency of initiation of retrotransposition
remains unchanged, while the length of de novo insertions is
compromised by inhibition of the RT enzyme. As such short
abortive insertions may also contribute to genomic instability this
raises an important caveat regarding the utility of nRTIs in a
therapeutic setting. Overall, a greater understanding of the
potential role of LINE-1 retrotransposition in physiological
processes would be required to evaluate the potential risks of
therapeutically suppressing LINE-1 retrotransposition.
The more immediate implications of our findings are related to
the in vitro study of LINE-1 function, where we have demonstrated
that nRTIs potently inhibit the generation of new LINE-1
insertions at concentrations that do not significantly impair
cellular DNA polymerase enzymes. This provides a proof of
principle for using nRTIs in studies aimed at testing the potential
role of LINE-1 in physiological processes, by examining the effects
of suppressing LINE-1 activity either in vitro or in animal models.
Materials and Methods
LINE-1 Retrotransposition assay
HeLa cells were plated at 10
5 cells per well in 6 well plates in
DMEM supplemented with 10% FBS (DMEM-10). The following
day, media was removed and replaced with DMEM-10 supple-
mented with either: stavudine, tenofovir disoproxil fumarate,
lamivudine, zidovudine, or nevirapine. Stavudine, lamivudine,
zidovudine and nevirapine were tested in triplicate at 25 mM,
5 mM, 1 mM, 0.2 mM, 0.04 mM, and 0.008 mM. Tenofovir
disoproxil fumarate was tested in triplicate at 11.30 mM,
2.26 mM, 0.45 mM, 0.09 mM, and 0.004 mM. No drug was added
to 6 wells for controls. Two hours after the addition of drugs a
retrotransposition assay was initiated as has been previously
described [29]. Briefly, cells were transfected with the LINE-1
retrotransposition reporter plasmid 99gfpLRE3 using FuGene HD
(Roche). For each transfection, 3 ml of FuGene HD was added to
100 ml of DMEM (no FBS), and mixed gently. 0.5 mgo f
99gfpLRE3 were then added to this solution and complex
formation was allowed to proceed for 15 minutes. The full volume
of transfection solution was then added to the plated HeLa cells,
and these were incubated overnight. Transfection controls were
performed in parallel with pEGFP-N1 (Clontech), and efficiencies
were determined 48 hour post-transfection by flow-cytometry. We
consistently observed 80–90% transfection efficiencies. The
following day, and on each subsequent day of the experiment,
the medium in each well was replaced with DMEM-10 containing
the corresponding concentration of drug, as well as 2.5 mg/ml
puromycin. Since the 99gfpLRE3 and 99gfpJM111 plasmids both
encode puromycin resistance markers, this allowed for selection of
cells that had been successfully transfected. Untransfected controls
were also subjected to selection with 2.5 mg/ml puromycin, and
consistently were killed within 2–3 days.
On day 5 post-transfection, media was removed fromall wells and
replaced with 1 ml of 0.5 mM EDTA in PBS. Incubation of cells in
this solution for 15 minutes at 37uC resulted in release of HeLa cells
from the plate. Cells were transferred to a 96 well plate and stained
with the viability dye 7-AAD (BD Pharmingen) following manufac-
turer’s instructions. FACS analysis was performed on unfixed cells
using the FACSCalibur system (BD). Retrotransposition frequency
was determined by gating on eGFP
+ cells, after exclusion of dead (7-
AAD bright) and apoptotic (7-AAD dim) cells.
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